Heart attacks occur when the flow of blood and oxygen to the heart is completely cut off due to a blocked coronary artery. In many cases, even if catheter-based interventions such as angioplasty and stenting lead to quick restoration of blood flow, the heart muscle is still irreversibly damaged, leaving patients with heart failure. SSO2 therapy after coronary intervention delivers localized, super-oxygenated blood to improve microvascular blood flow and reduces damage to the blood vessels and downstream heart muscle.
SSO2 therapy has been shown in multiple randomized prospective clinical trials to consistently and safely reduce damage and scarring (infarct size) in anterior heart attack patients. Decades of research on heart attack patients has demonstrated that infarct size reduction is correlated with improved survival and left ventricular function as well as decreased risk for heart failure.
The treatment delivers hyperoxemic levels of dissolved oxygen — seven to 10 times normal levels — directly to the damaged heart muscle once the coronary artery is successfully opened. It is indicated for patients who are treated within six hours of symptom onset for the most serious kind of heart attacks, left anterior descending ST-elevation myocardial infarction.
“Although the interventional approach to treating heart attacks has continuously been refined over the past several decades, the long-term prognosis for patients with large, anterior heart attacks has not improved in a commensurate fashion,” said Sandeep Nathan, MD, MS, Associate Professor of Medicine, Co-Director of the Cardiac Catheterization Laboratory and Director of the Cardiac Intensive Care Unit at UChicago Medicine. “We are pleased to lead the way in Illinois with what seems to be a very promising, new treatment for some of the highest-risk patients we routinely see in the cardiac catheterization lab.”
SSO2 therapy, branded as TherOx, was developed by California-based ZOLL.
About the University of Chicago Medicine & Biological Sciences
The University of Chicago Medicine, with a history dating back to 1927, is one of the nation’s leading academic health systems. It unites the missions of the University of Chicago Medical Center, Pritzker School of Medicine and the Biological Sciences Division. Twelve Nobel Prize winners in physiology or medicine have been affiliated with the University of Chicago Medicine. Its main Hyde Park campus is home to the Center for Care and Discovery, Bernard Mitchell Hospital, Comer Children’s Hospital and the Duchossois Center for Advanced Medicine. It also has ambulatory facilities in Orland Park, South Loop, Homewood and River East as well as affiliations and partnerships that create a regional network of care. UChicago Medicine offers a full range of specialty-care services for adults and children through more than 40 institutes and centers including an NCI-designated Comprehensive Cancer Center. Together with Harvey-based Ingalls Memorial, UChicago Medicine has 1,296 licensed beds, nearly 1,300 attending physicians, over 2,800 nurses and about 970 residents and fellows.
Visit UChicago Medicine’s health and science news blog at www.uchicagomedicine.org/forefront.